EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Preventing Skeletal-Related Events in Newly Diagnosed Multiple Myeloma

Benjamin Massat iD, Patrick Stiff, Fatema Esmail, Estefania Gauto-Mariotti, Patrick Hagen iD

Cells · 2025

DOI: 10.3390/cells14161263 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, 2025. Verfasst von Benjamin Massat und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Department of Medicine, Loyola University Medical Center, Maywood, IL 60153, USA. Hauptthemen laut MEDLINE: Bone Density Conservation Agents, Bone Diseases, Denosumab, Multiple Myeloma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite the increasing number of novel therapies to treat newly diagnosed multiple myeloma (NDMM), preventing skeletal-related events (SREs) remains a challenge. This review summarizes the mechanistic causes of myeloma bone disease, data supporting the use of bisphosphonates and RANKL inhibitors, and the optimal management of preventing SREs in NDMM patients. Both zoledronic acid (ZA) and denosumab are acceptable treatment options with comparable safety and efficacy profiles. However, in patients who are candidates for autologous stem cell transplant (ASCT), denosumab may be preferred over ZA due to a progression-free survival (PFS) benefit observed in post hoc analyses when used with proteasome inhibitor-based regimens. The optimal duration of bone-directed therapy is unclear, but it is typically given for two years. Supportive care should include dental evaluation at baseline, annually, and if symptoms appear, given the risk for jaw osteonecrosis with both ZA and denosumab. Both drugs should be held in the setting of dental work. Patients should receive adequate calcium and vitamin D supplementation. Supportive procedures such as cement augmentation, radiation, and orthopedic surgery can also help treat compression fractures, uncontrolled pain, cord compression, and pathologic fractures. We conclude with our approach for managing SREs and a review of novel therapies and targets.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bone Density Conservation AgentsBone DiseasesDenosumabMultiple MyelomaDiphosphonatesHumansDisease ManagementRANK LigandZoledronic Acid

Stichwörter der Autor:innen

denosumabmultiple myelomaskeletal-related eventszoledronic acid

Substanzen

Bone Density Conservation AgentsDenosumabRANK LigandTNFSF11 protein, humanZoledronic AcidDiphosphonates

Autor:innen und Institutionen

  • Division of Hematology and Oncology, Department of Medicine, Loyola University Medical Center, Maywood, IL 60153, USA.

ORCID-Profile: Benjamin Massat, Patrick Hagen

Zitieren

APA

Massat, B., Stiff, P., Esmail, F., Gauto-Mariotti, E., & Hagen, P. (2025). Preventing Skeletal-Related Events in Newly Diagnosed Multiple Myeloma. Cells. https://doi.org/10.3390/cells14161263

Vancouver

Massat B, Stiff P, Esmail F, Gauto-Mariotti E, Hagen P. Preventing Skeletal-Related Events in Newly Diagnosed Multiple Myeloma. Cells. 2025. doi:10.3390/cells14161263

BibTeX
@article{Massat2025,
  author = {Massat, Benjamin and Stiff, Patrick and Esmail, Fatema and Gauto-Mariotti, Estefania and Hagen, Patrick},
  title = {Preventing Skeletal-Related Events in Newly Diagnosed Multiple Myeloma},
  journal = {Cells},
  year = {2025},
  doi = {10.3390/cells14161263}
}
Kostenlos starten →